A Study of Ropivacaine Complex Methylene Blue Fascia Iliaca Compartment Block on Analgesia in Patients Undergoing Hip Arthroplasty

Wang wanxia

Status: Completed

Conditions: Femoral Neck Disease

Treatments: Drug: Ropivacaine combined with methylene blue for iliac fascia block

Study type: Interventional

Funder types: Other

Identifiers

NCT06284941

KY 2023-001-001

Details and patient eligibility

About

Total hip arthroplasty is currently the most effective method for treating hip joint lesions and improving quality of life, but postoperative severe pain is not conducive to rapid recovery of patients. In recent years, the widespread application of ultrasound has achieved good clinical results in iliac fascia block for postoperative analgesia in THA. However, the use of high-dose local anesthetics can increase the risk of local anesthetic poisoning, and the single block analgesia time is generally less than 24 hours. Methylene blue, as a long-acting analgesic drug, can block the pain transmission of nerve fibers for a long time, achieving analgesic effects without damaging neurons. This study used ultrasound-guided ropivacaine combined with methylene blue to perform iliac fascia block on patients undergoing total hip replacement, with the aim of prolonging pain relief time, reducing complications, and promoting postoperative recovery on the basis of traditional methods.

Enrollment: 90 patients

Sex: All

Ages: 65 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hip replacement surgery is indicated
• ASA Class II - Class III
• No history of analgesic or local anesthetic allergy
• No history of alcohol abuse or narcotic drug abuse
• Patients and their families have given informed consent and signed the informed consent form

Exclusion criteria

• Patient or family refusal to participate in the study
• Severe coagulation abnormalities
• Local anesthetic allergy
• Severe psychiatric illness or other communication disorder
• There is an infection at the puncture site
• History of neurological disease such as Guillain-Barré syndrome
• Delay in awakening post-surgery for more than 60 min,
• Post-surgical use of an analgesic pump
• Inability to follow-up at the required time points.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

90 participants in 2 patient groups

0.25% ropivacaine 30ml for iliac fascia block

No Intervention group

0.25% ropivacaine+0.05% methylene blue 30ml for iliac fascia block

Experimental group

Treatment:

Drug: Ropivacaine combined with methylene blue for iliac fascia block